Lipids & Cholesterol Disorders News | LDL, HDL Treatment Studies

Lipids and Cholesterol


Latest News

FDA Panel Votes on Vascepa for Cardiovascular Risk Reduction

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted in favor (16-0) to recommend the approval of Vascepa (icosapent ethyl capsules; Amarin) to reduce residual cardiovascular (CV) risk in patients with statin-managed low density lipoprotein (LDL) cholesterol, but persistent elevated triglycerides.